Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | PRKCB | P05771 | 16/20 | 1.00 |
| ▸ | PRKCG | P05129 | 16/20 | 1.00 |
| ▸ | PRKCA | P17252 | 15/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.89 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.85 |
| ▸ | CDK1 | P06493 | 3/20 | 0.80 |
| ▸ | CDK2 | P24941 | 2/20 | 0.80 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.80 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.69 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.69 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.69 |
| ▸ | PRKACA | P17612 | 1/20 | 0.69 |
| ▸ | PRKACG | P22612 | 1/20 | 0.69 |
| ▸ | PRKACB | P22694 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.69 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.69 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344559 | 0.94 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL4336077 | 0.92 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL14522451 | 0.91 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL25778145 | 0.90 | GSK3B (0.90) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL4342534 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| Indolylylmaleimide 2 SCHEMBL4341971 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL4345338 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL6417102 | 0.89 | GSK3B (1.00) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL22765525 | 0.88 | GSK3B (0.97) | GSK3BPRKCBPRKCGPRKCAPRKCE | |
| SCHEMBL14522441 | 0.84 | GSK3B (0.85) | GSK3BPRKCBPRKCGPRKCAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1345946-B1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCB 61/4885PRKCG 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.